Alpha Biopharma (2)

Executive Summary

Alpha Biopharma is a clinical-stage biotechnology company based in Shanghai, China, focused on developing innovative oncology therapeutics including antibodies and small molecules. Founded in 2012, the company targets specific genetic drivers of cancer through a pipeline of targeted therapies. Its lead program is in Phase 2, and the company combines internal discovery with strategic collaborations. Despite a lack of disclosed pipeline details, Alpha Biopharma's focus on precision oncology and its clinical-stage assets position it for potential value inflection points in the near term.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for lead targeted therapy45% success
• Q4 2026Potential partnership or licensing deal for preclinical asset35% success